Smith, Caroline L. and Vallance, Patrick (2005) Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disorders. Current Pharmaceutical Design, 11 (17). pp. 2177-2185. ISSN 1381-6128
Official URL: http://dx.doi.org/10.2174/1381612054367364
Asymmetric dimethylarginine (ADMA) is an endogenously occurring methylarginine that inhibits nitric oxide synthesis. Plasma levels of methylarginines increase in renal failure and certain cardiovascular pathologies, and in patients with end stage renal failure the level of ADMA predicts the risk of cardiovascular events and overall mortality. The object of this review is to describe the mechanisms of ADMA synthesis, metabolism and uptake and to outline techniques for measuring ADMA and the pathological states in which ADMA levels are altered.
|Uncontrolled Keywords:||Nitric oxide (no), nitric oxide synthases (nos), nadph, protein arginine methyltransferases (prmt), single nucleotide polymorphisms (snp), angiogenesis, arginine, cardiovascular disorders, pre-eclampsia|
|Research Community:||University of Westminster > Life Sciences, School of|
|Deposited On:||30 May 2006|
|Last Modified:||11 Aug 2010 15:30|
Repository Staff Only: item control page